报价延迟最少15分钟:2025/07/17 07:43 EDT
盘前时段
|
||||
|
26.08 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
26.08
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.50/-1.54
|
|
企业价值
1.90B
|
| 资产负债 |
|
每股账面净值
9.25
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.14M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/17 07:43 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
